Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity

C F Nathan, H W Murray, M E Wiebe, B Y Rubin, C F Nathan, H W Murray, M E Wiebe, B Y Rubin

Abstract

Human blood mononuclear leukocytes stimulated with toxoplasma antigen, concanavalin A, mezerein plus lentil lectin, or staphylococcal enterotoxin A secreted a factor (macrophage-activating factor, or MAF) that enhanced the capacity of human macrophages to release H2O2 and to kill toxoplasmas. The same lymphoid supernatants contained IFN gamma but not IFN alpha or IFN beta. The MAF activity of six of seven unfractionated supernatants was completely eliminated by a monoclonal antibody that neutralizes IFN gamma, and MAF in the remaining supernatant was almost completely neutralized. Native IFN gamma partially purified by two independent protocols to specific activities of 1 X 10(6) and 10(7) U/mg protein was enriched in MAF activity at least as much as in antiviral activity. The capacity of macrophages to secrete H2O2 after incubation in partially purified native IFN gamma (mean peak stimulation, 8.8-fold) was greater than with unpurified lymphokines (3.8-fold) and sometimes equaled or exceeded the capacity of freshly harvested monocytes. The MAF activity of the partially purified native IFN gamma preparations was abolished by monoclonal anti-IFN gamma. Finally, IFN gamma of greater than 99% estimated purity was isolated (at Genentech, Inc.) from bacteria transformed with the cloned human gene for this lymphokine. Recombinant IFN gamma had potent MAF activity, stimulating the peroxide-releasing capacity of macrophages an average of 19.8-fold at peak response and enhancing their ability to kill toxoplasmas from 2.6 +/- 1.3% for untreated cells to 54 +/- 0.4% for treated cells. Attainment of 50% of the maximal elevation in peroxide-releasing capacity required a geometric mean concentration of 0.1 antiviral U/ml of recombinant IFN gamma, which is estimated to be approximately 6 picomolar for this preparation. Peroxide secretory capacity and toxoplasmacidal activity of macrophages peaked 2-4 d after exposure to IFN gamma. Peroxide-secretory capacity remained elevated during at least 6 d of continuous exposure, but the effect of IFN gamma was reversed within about 3 d of its removal. Activation was usually but not invariably accompanied by characteristic changes in cell morphology. Thus, IFN gamma activates human macrophage oxidative metabolism and antimicrobial activity, and appeared to be the only factor consistently capable of doing so in the diverse LK preparations tested.

References

    1. Ann N Y Acad Sci. 1980;350:72-90
    1. J Exp Med. 1975 Feb 1;141(2):483-96
    1. J Exp Med. 1982 Dec 1;156(6):1780-93
    1. J Immunol. 1983 Apr;130(4):1492-4
    1. J Immunol. 1983 May;130(5):2011-3
    1. Infect Immun. 1979 Dec;26(3):949-55
    1. Jpn J Microbiol. 1975 Jun;19(3):235-6
    1. Zentralbl Bakteriol Mikrobiol Hyg A. 1981 Dec;251(1):134-43
    1. Microbiol Immunol. 1980;24(11):1109-20
    1. Nature. 1970 Sep 26;227(5265):1350-1
    1. Nature. 1982 Aug 26;298(5877):859-63
    1. J Exp Med. 1969 May 1;129(5):973-92
    1. Nucleic Acids Res. 1982 Apr 24;10(8):2487-501
    1. Science. 1965 Jul 16;149(3681):310-1
    1. J Clin Invest. 1981 Nov;68(5):1243-52
    1. J Exp Med. 1982 Jul 1;156(1):112-27
    1. J Exp Med. 1971 Jun 1;133(6):1356-76
    1. J Immunol. 1983 Mar;130(3):1019-20
    1. FEBS Lett. 1981 Jul 6;129(2):233-6
    1. Infect Immun. 1971 Oct;4(4):337-43
    1. Science. 1968 Aug 23;161(3843):804-6
    1. J Immunol. 1983 Apr;130(4):1784-9
    1. J Interferon Res. 1980 Fall;1(1):137-45
    1. J Immunol. 1982 Jan;128(1):123-8
    1. Infect Immun. 1971 Jun;3(6):819-24
    1. Cell Immunol. 1980 Mar 1;50(1):177-90
    1. Nature. 1982 Feb 11;295(5849):503-8
    1. J Exp Med. 1973 Feb 1;137(2):275-90
    1. J Exp Med. 1973 Oct 1;138(4):952-64
    1. J Immunol. 1976 Aug;117(2):381-7
    1. Infect Immun. 1981 Oct;34(1):131-9
    1. J Biol Chem. 1978 Nov 10;253(21):7612-5
    1. J Bacteriol. 1966 Jun;91(6):2185-91
    1. J Exp Med. 1979 Oct 1;150(4):950-64
    1. J Biol Chem. 1951 Nov;193(1):265-75
    1. J Reticuloendothel Soc. 1981 Mar;29(3):181-92
    1. Infect Immun. 1973 Jan;7(1):68-75
    1. Infect Immun. 1972 Mar;5(3):370-6
    1. J Exp Med. 1978 Jul 1;148(1):288-300
    1. J Interferon Res. 1982;2(3):377-86
    1. J Exp Med. 1981 May 1;153(5):1068-79
    1. J Clin Invest. 1982 May;69(5):1099-111
    1. Immunology. 1982 Apr;45(4):621-8
    1. Science. 1969 Jun 20;164(3886):1415-7
    1. J Exp Med. 1982 Oct 1;156(4):945-61
    1. Proc Natl Acad Sci U S A. 1980 Oct;77(10):5928-32
    1. J Exp Med. 1980 Dec 1;152(6):1596-609
    1. J Clin Invest. 1983 Jul;72(1):32-44
    1. J Clin Invest. 1982 Nov;70(5):1042-8
    1. J Exp Med. 1979 May 1;149(5):1056-68

Source: PubMed

3
Předplatit